HoFH, the International Clinical Collaborators Registry
Recruiting · NCT04815005 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of Pennsylvania
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder caused by bi-allelic mutations in the LDL Receptor pathway, is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) from birth and premature atherosclerotic cardiovascular disease (ASCVD). Our current knowledge about HoFH is disjointed and largely stems from relatively small case series and expert opinion. HICC (Homozygous FH International Clinical Collaborators) is a global consortium of clinicians who are contributing de-identified data of patients diagnosed with HoFH with the goal to advance our understanding of this rare disease.
Who can take part
Inclusion criteria
- Diagnosis of homozygous familial hypercholesterolemia (HoFH) clinically of genetically determined
Exclusion criteria
- No diagnosis of HoFH
Where it is running
4 locations listed across 1 US state.
- University of Pennsylvania - Philadelphia, Pennsylvania, United States
- Department of Vascular Medicine, Amsterdam UMC - Amsterdam, Netherlands
- Department of Medicine, Division of Lipidology and Hatter Institute for Cardiovascular Research in Africa, University of Cape Town - Cape Town, South Africa
- c. Carbohydrate and Lipid Metabolism Research Unit, Faculty of Health Sciences, University of Witwatersrand - Johannesburg, South Africa